Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving warfarin therapy for at least 3 months, administered to achieve an international normalized ratio (INR) range of 2.0 to 3.0~* Requiring temporary interruption of warfarin for pre-specified elective procedure or surgery~* Presence of one of the following conditions:~  1. Chronic (permanent or paroxysmal) nonvalvular atrial fibrillation, confirmed by at least one prior electrocardiography recording or pacemaker or acid citrate dextrose (ACD) interrogation~ 2. Chronic (permanent or paroxysmal) valvular atrial fibrillation with evidence of mitral valvular heart disease, confirmed by the same criteria as nonvalvular atrial fibrillation~* Presence of at least one of the following major stroke risk factors:~  1. Older than 75 years of age~ 2. Hypertension~ 3. Diabetes mellitus~ 4. Congestive heart failure or left ventricular dysfunction~ 5. Previous ischemic stroke, systemic embolism, or transient ischemic attack (TIA)~Exclusion Criteria:~* Any mechanical prosthetic heart valve~* Stroke (ischemic or hemorrhagic), systemic embolism, or TIA within the past 12 weeks~* Venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) within past 12 weeks~* Major bleeding within the past 6 weeks~* Severe renal insufficiency, measured through a calculated creatinine clearance of less than 30 mL/min~* Thrombocytopenia~* Life expectancy less than 1 month~* Condition that impairs compliance with trial protocol, such as cognitive impairment, an uncontrolled psychiatric condition, or geographic inaccessibility~* Pregnancy~* Allergy to heparin or history of heparin-induced thrombocytopenia~* Having one of the following surgeries or procedures during warfarin interruption:~  1. Cardiac surgery, such as coronary artery bypass or heart valve replacement~ 2. Neurosurgery that is intracranial or intraspinal, such as tumor resection or aneurysm repair~ 3. High-risk non-surgical procedures, such as brain biopsy~* Other surgical or non-surgical procedure that, at the discretion of the surgeon, precludes administration of therapeutic-dose low molecular weight heparin (LMWH) at any time in the post-procedure period~* More than one surgery planned during the trial period~* Prior participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Dalteparin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).